Qiagen NV

Type: Company
Name: Qiagen NV
Nationality: Netherlands
Web Address: http://www.qiagen.com/
Fact Sheet: Fact Sheet for Qiagen NV
First reported 6 hours ago - Updated 33 mins ago - 1 reports

AstraZeneca share price: Drugmaker unveils partnership with gene sequencing group

iNVEZZ.com, Thursday, August 21: AstraZeneca Plc (LON:AZN) has struck a collaboration deal with biotech group Illumina Inc (NASDAQ: ILMN) to develop a next-generation gene sequencing platform for diagnostic tests which will be used for the Anglo-Swedish ... [Published Invezz - 6 hours ago]
First reported 5 hours ago - Updated 48 mins ago - 1 reports

AstraZeneca and Illumina to ally to create companion cancer diagnostics

:09 in Pharmaceutical Company Product News AstraZeneca and Illumina have announced a new alliance that will accelerate the development of companion diagnostic tests for cancer therapies. The deal will see Illumina develop its next-generation sequencing ... [Published Zenopa - 5 hours ago]
First reported Aug 20 2014 - Updated 22 hours ago - 1 reports

AstraZeneca share price: Group inks diabetes research deal with Mitsubishi Tanabe

iNVEZZ.com, Wednesday, August 20: AstraZeneca Plc (LON:AZN) has signed a three-year research deal into diabetic nephropathy, or kidney failure due to diabetes, with Japan’s Mitsubishi Tanabe Pharma Corp (TYO:4508), the two companies have said.As of 09:57 ... [Published Invezz - Aug 20 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

QIAGEN agrees with BGI Tech to provide services based on the Human Gene Mutation Database (HGMD) in Greater China

Shenzhen, China and Wolfenbuettel, Germany, July 29, 2014-QIAGEN and BGI Tech Solutions Co., Ltd. (BGI Tech), a subsidiary of BGI, the world's largest genomics organization, today announced that they have entered into a distribution and service agreement ... [Published Noodls - Aug 19 2014]
First reported Aug 07 2014 - Updated Aug 08 2014 - 2 reports

Qiagen (QGEN) Showing Resistance Near $23.81

After Thursday’s trading in Qiagen NV (QGEN) the algorithms behind MarketIntelligenceCenter.com's Artifical Intelligence Center picked out a trade that offers a 4.65% or 16.02% (for comparison purposes only), while providing 8.51% downside protection. ... [Published MarketIntelligenceCenter.com - Aug 08 2014]
Entities: Qiagen NV, Intelligence
First reported Jul 31 2014 - Updated Jul 31 2014 - 2 reports

QIAGEN agrees with BGI Tech to provide services based on the Human Gene Mutation Database (HGMD) in Greater China

Under the agreement, BGI Tech will serve the Chinese market including providing first level support for the database.In recent years, next-generation sequencing (NGS) has provided significant impetus for scientific progress, which is expected to have ... [Published 4 Traders - Jul 31 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 5 reports

Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina

DUBLIN, July 31, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Genomics Market 2014-2018" report to their offering.http://photos.prnewswire.com/prnh/20130307/600769Genomics is the study of the genetic material or ... [Published PR Newswire: General Business - Jul 31 2014]
First reported Jul 29 2014 - Updated Jul 30 2014 - 4 reports

Qiagen NV's (QGEN) CEO Peer Schatz on Q2 2014 Results - Earnings Call Transcript

OperatorLadies and gentlemen, thank you for standing by. I am Patrick Wright, your Chorus Call operator. Welcome, and thank you for joining Qiagen's Conference Call to discuss results for the Quarter 2 of 2014. [Operator Instructions] Please be advised ... [Published Seeking Alpha - Jul 30 2014]
First reported Jul 29 2014 - Updated Jul 30 2014 - 8 reports

Qiagen (QGEN) Showing Bullish Technicals With Resistance At $25.55

The patented option trade-picking algorithms behind MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered call trade on Qiagen NV (QGEN) that includes 6.75% downside protection.Sell one contract of the Nov. '14 $25.00 call ... [Published Market Intelligence Center - Jul 30 2014]
First reported Jul 29 2014 - Updated Jul 30 2014 - 3 reports

AstraZeneca, Qiagen Partner For IRESS Companion Test In NSCLC

By Estel Grace MasangkayNetherlands-based sample and assays technologies company Qiagen announced that it has entered into partnership with British pharma giant AstraZeneca for the development and marketing of a liquid biopsy-based companion diagnostic ... [Published Bioresearch Online - Jul 29 2014]
First reported Jul 28 2014 - Updated Jul 29 2014 - 21 reports

Qiagen partners with AstraZeneca on diagnostic companion for gefitinib in NSCLC

Qiagen recently announced a collaboration agreement with AstraZeneca for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with its non–small-cell lung cancer treatment, gefitinib.The project builds on ... [Published Orthopedics Today - Jul 29 2014]
First reported Jul 25 2014 - Updated Jul 26 2014 - 3 reports

QIAGEN Licenses Blood Cancer Biomarkers

Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including NGS gene panels, for blood cancers. ... [Published Technology Networks - Jul 26 2014]

Quotes

...Ruth March, vice-president for personalised healthcare and biomarkers at AstraZeneca, said: "Our aim is for doctors to be able to use these tests to prescribe the right medicines for the right patients - bringing benefits to healthcare professionals, payers and patients alike." This is the third personalised medicine collaboration to be signed by AstraZeneca in recent weeks, following previous deals with Roche and Qiagen
"Bioinformatics has become crucial to managing the data and identifying meaningful connections"
"Known for their outstanding contributions to science, BGI is committed to excellence in everything they do, and want only the best-in-class solutions for their customers. Assessing mutations is an important need for many of their customers, so it is logical for them to represent HGMD. New and existing HGMD customers in Greater China will benefit from local support and from a distributor with deep subject-matter expertise." said Frank Schacherer, CTO of BIOBASE
".....Five participants in whom resting CD4+ T-cell-associated HIV RNA (rc-RNA) increased after a single dose of VOR agreed to receive daily VOR Monday through Wednesday for 8 weekly cycles....HDAC inhibitors are currently leading candidates for use as therapeutic agents to attack latent HIV infection. There is a widely held expectation that eradication of HIV infection will require the use of combination therapy to efficiently disrupt latent infection and the use of vaccines or immunotherapy to assist in clearing latent HIV infection.....In contrast to the changes seen after an initial dose of VOR, in 5 participants who received a total of 22 400-mg doses of VOR during a 4-month period, cellular acetylation and rc-RNA were increased only minimally when measured shortly after doses 11 and 22. Given the complex modulation of numerous cellular genes by VOR and the fact that cellular acetylation remains modestly up-regulated 24 hours after VOR exposure, compensatory cellular effects that follow VOR administration may blunt subsequent response to additional VOR doses during the 24-hour dosing interval tested. We hypothesize that a longer interdose interval may be required to allow cellular mechanisms to be resensitized to HDAC inhibition and to observe robust and reproducible induction of latent HIV proviral expression."

More Content

All (414) | News (245) | Reports (1) | Blogs (93) | Audio/Video (0) | Fact Sheets (3) | Press Releases (72)
sort by: Date | Relevance
Global Molecular Biology Enzymes, Kits, & Reage... [Published TVNewsCheck - 3 hours ago]
AstraZeneca and Illumina to ally to create comp... [Published Zenopa - 5 hours ago]
AstraZeneca share price: Drugmaker unveils part... [Published Invezz - 6 hours ago]
Molecular Diagnostics Market by Technology (PCR... [Published Individual.com - 8 hours ago]
ASTRAZENECA : Announces partnership with illumi... [Published 4 Traders - 10 hours ago]
Bioinformatics: the next big thing in life scie... [Published pharmaphorum - Aug 20 2014]
AstraZeneca share price: Group inks diabetes re... [Published Invezz - Aug 20 2014]
Selective HDAC Inhibition for the Disruption of... [Published Plosone.org - Aug 20 2014]
QIAGEN agrees with BGI Tech to provide services... [Published Noodls - Aug 19 2014]
DGAP-CMS: QIAGEN N.V.: Release of a capital mar... [Published GlobeNewswire: Acquisitions News - Aug 19 2014]
Announcing Speakers at BioConference Live Genet... [Published PRWeb - Aug 19 2014]
DGAP-DD: QIAGEN N.V. english [Published GlobeNewswire: Acquisitions News - Aug 18 2014]
Can bovine leukemia virus cause cancer in humans? [Published Food Consumer - Aug 16 2014]
Neuronal Cellular Responses to Extremely Low Fr... [Published Plosone.org - Aug 16 2014]
The X Gene of Adeno-Associated Virus 2 (AAV2) I... [Published Plosone.org - Aug 16 2014]
HIV-1 Expression Within Resting CD4+ T Cells Af... [Published National AIDS Treatment Advocacy Project - Aug 15 2014]
Researchers Identify Tests to Diagnose Invasive... [Published theCSRfeed - Aug 14 2014]
World Genomics Market is Expected to Reach USD ... [Published PR.com Press Releases - Aug 14 2014]
The Worldwide Market for In Vitro Diagnostic Te... [Published MarketResearch.com - Aug 14 2014]
Whole Blood DNA Extraction Methods Compared [Published Lab Medica - Aug 14 2014]
Complexin inhibits spontaneous release and sync... [Published Elifesciences - Aug 14 2014]
Shares of QIAGEN Receive a Boost, Up 1.4... [Published Financial News Network online - Aug 13 2014]
Researchers identify tests to diagnose invasive... [Published EurekAlert! - Aug 13 2014]
QIAGEN, BGI Tech Database Agreement [Published Technology Networks - Aug 13 2014]
Molecular Biology Enzymes, Kits & Reagents Mark... [Published PRWeb - Aug 13 2014]
Qiagen (QGEN) Showing Bearish Technicals With R... [Published MarketIntelligenceCenter.com - Aug 13 2014]
Exact Sciences bags FDA approval and proposed C... [Published FierceMedicalDevices - Aug 13 2014]
Qiagen (QGEN) Trading Near $23.51 Support Level [Published Individual.com - Aug 12 2014]
BioHealth Innovation, Inc. Bolsters Board of Di... [Published PR Newswire - Aug 12 2014]
Qiagen (QGEN) Trading Near $23.51 Support Level [Published MarketIntelligenceCenter.com - Aug 12 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Researchers Identify Tests to Diagnose Invasive... [Published theCSRfeed - Aug 14 2014]
Early, more accurate detection of this potentially deadly fungus can improve patient outcomes, according to new report in The Journal of Molecular Diagnostics SOURCE: Elsevier DESCRIPTION: Philadelphia, PA, August 14, 2014 /3BL Media/ – The fungal ...
World Genomics Market is Expected to Reach USD ... [Published PR.com Press Releases - Aug 14 2014]
San Francisco, CA, August 14, 2014 --( PR.com )-- The global market for genomics is expected to reach USD 22.1 billion by 2020, growing at an estimated CAGR of 10.3% from 2014 to 2020, according to a new study by Grand View Research, Inc. Genomics play ...
Qiagen (QGEN) Showing Bearish Technicals With R... [Published MarketIntelligenceCenter.com - Aug 13 2014]
A covered call identified by MarketIntelligececenter.com's patented algorithm on Qiagen NV (QGEN) could yield about 3.97% (14.36% annualized, for comparison purposes only) in 101 days. Pair a long position in the stock with the Nov. '14 $22.50 call for ...
Qiagen (QGEN) Trading Near $23.51 Support Level [Published MarketIntelligenceCenter.com - Aug 12 2014]
The patented algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center found a trading opportunity with Qiagen NV (QGEN) that should provide a 4.21% return in just 102 days. Sell one Nov. '14 call at the $22.50 level for each ...
Qiagen (QGEN) Showing Resistance Near $23.81 [Published MarketIntelligenceCenter.com - Aug 08 2014]
After Thursday’s trading in Qiagen NV (QGEN) the algorithms behind MarketIntelligenceCenter.com's Artifical Intelligence Center picked out a trade that offers a 4.65% or 16.02% (for comparison purposes only), while providing 8.51% downside protection. ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
DGAP-CMS: QIAGEN N.V.: Release of a capital mar... [Published GlobeNewswire: Acquisitions News - Aug 19 2014]
DGAP-DD: QIAGEN N.V. english [Published GlobeNewswire: Acquisitions News - Aug 18 2014]
DGAP-CMS: QIAGEN N.V.: Release of a capital mar... [Published GlobeNewswire: Advertising News - Aug 11 2014]
DGAP-CMS: QIAGEN N.V.: Release according to Art... [Published GlobeNewswire: Acquisitions News - Jul 31 2014]
Global Genomics Market 2014-2018: Key Vendors a... [Published GlobeNewswire: Acquisitions News - Jul 31 2014]
1 2 3 4 5 6 7 8 9 10 ...
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.